References
1. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332-1343.
2. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50(6):1227-1235.
3. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052.
4. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
5. Ravelli A, Minoia F, Davi S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68(3):566-576.
6. Parodi A, Davi S, Pringe AB, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60(11):3388-3399.
7. Rungrojjananon N, Pakakasama S, Winaichatsak A, et al. Pediatric hemophagocytic lymphohistiocytosis in a tropical country: Results of a multicenter study in Thailand. Asia Pac J Clin Oncol. 2023;19(2):e128-e137.
8. Bin Q, Gao JH, Luo JM. Prognostic factors of early outcome in pediatric hemophagocytic lymphohistiocytosis: an analysis of 116 cases. Ann Hematol. 2016;95(9):1411-1418.
9. Xu XJ, Wang HS, Ju XL, et al. Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: A retrospective multicenter study. Pediatr Blood Cancer. 2017;64(4):e26264.
10. Yanagaisawa R, Matsuda K, Ohga S, et al. Factors predicting the recurrence of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol. Int J Hematol. 2019;109(5):612-617.
11. Debaugnies F, Mahadeb B, Ferster A, et al. Performances of the H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adult and Pediatric Patients. Am J Clin Pathol. 2016;145(6):862-870.
12. Matics TJ, Sanchez-Pinto LN. Adaptation and Validation of a Pediatric Sequential Organ Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children. JAMA Pediatr. 2017;171(10):e172352.
13. Padungmaneesub W, Reungrongrat S, Manowong S, et al. Biomarkers of disseminated intravascular coagulation in pediatric intensive care unit in Thailand. Int J Lab Hematol. 2019;41(1):32-38.
14. Chanthong S, Choed-Amphai C, Manowong S, et al. Rotational Thromboelastometry and Clot Waveform Analysis as Point-of-Care Tests for Diagnosis of Disseminated Intravascular Coagulation in Critically Ill Children in Thailand. Pediatr Crit Care Med. 2024 Feb 1. [online ahead of print].
15. Hines MR, von Bahr Greenwood T, Beutel G, et al. Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. Crit Care Med. 2022;50(5):860-872.
16. Marsh RA, Jordan MB, Talano JA, et al. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience. Pediatr Blood Cancer. 2017;64(4).
17. Kaya Z, Bay A, Albayrak M, et al. Prognostic Factors and Long-Term Outcome in 52 Turkish Children With Hemophagocytic Lymphohistiocytosis. Pediatr Crit Care Med. 2015;16(6):e165-173.
18. Koh KN, Im HJ, Chung NG, et al. Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea Histiocytosis Working Party. Eur J Haematol. 2015;94(1):51-59.
19. Wang YR, Qiu YN, Bai Y, Wang XF. A retrospective analysis of 56 children with hemophagocytic lymphohistiocytosis. J Blood Med. 2016;7:227-231.
20. Beken B, Aytac S, Balta G, et al. The clinical and laboratory evaluation of familial hemophagocytic lymphohistiocytosis and the importance of hepatic and spinal cord involvement: a single center experience. Haematologica. 2018;103(2):231-236.
21. Goldman J, Desai MS, McClain KL, et al. Hepatobiliary Dysfunction and Disseminated Intravascular Coagulation Increase Risk of Mortality in Pediatric Hemophagocytic Lymphohistiocytosis. Pediatr Crit Care Med. 2018;19(10):e522-e530.
22. Li X, Yan H, Zhang X, et al. Clinical profiles and risk factors of 7-day and 30-day mortality among 160 pediatric patients with hemophagocytic lymphohistiocytosis. Orphanet J Rare Dis. 2020;15(1):229.
23. Cui Y, Shi J, Lu G, et al. Prognostic death factors in secondary hemophagocytic lymphohistiocytosis children with multiple organ dysfunction syndrome receiving continuous renal replacement therapy: A multicenter prospective nested case-control study. Ther Apher Dial. 2022;26(5):1023-1029.
24. Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929.
FIGURE 1 Receiver Operating Characteristic (ROC) curves for predicting R/R HLH using age and pSOFA score. (A) ROC curve for age with a cutoff of less than 3 years, demonstrating an AUC of 0.69 and a 95% CI of 0.59 – 0.79. (B) ROC curve for pSOFA score with a cutoff of ≥ 8, showing an AUC of 0.76 and a 95% CI of 0.66 – 0.86.
FIGURE 2 (A) Kaplan-Meier Survival Curves showing Overall Survival (OS) in childhood HLH, indicating a 5-year OS rate of 55.9% (95% CI 42.0 – 67.7%). (B) Comparison of 5-year OS rates between groups: 87.2% (95% CI 72.9 – 94.2%) in the non-R/R HLH group versus 9.0% (95% CI 1.7 – 24.0%) in the R/R HLH group (p < 0.001).